Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye drug EYE103 aims to restore vision in macular degeneration and vein occlusion

NCT ID NCT07205887

Disease control Sponsor: EyeBiotech Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 04, 2026 · Updated 3 times

Summary

This Phase 2 trial tests an experimental drug called EYE103 (Restoret) in 160 people with wet age-related macular degeneration or macular edema from a branch retinal vein occlusion. Participants receive three eye injections of either a low or high dose of EYE103, spaced four weeks apart. The study measures changes in vision and retinal thickness over 12 weeks to see if the drug can improve outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
EYE103 (Restoret), a humanized antibody injected into the eye
What this could lead to
If successful, this could lead to a new treatment option for wet age-related macular degeneration and macular edema from retinal vein occlusion, potentially improving vision and reducing retinal swelling.
What could go wrong
This is an early Phase 2 trial with only 160 participants, so results may not apply to everyone. The drug is still experimental, and side effects from eye injections (like infection or inflammation) are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 160 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Key General Inclusion Criteria • Be willing and able to understand the study procedures and the risks involved and provide written informed consent before the first study-related activity Key Neovascular Age-related Macular Degeneration (NVAMD)-specific Inclusion Criteria * Be ≥ 50 years of age * Have treatment naive subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) or juxtafoveal/extrafoveal CNV with foveal involvement * For participants who are treatment naïve for NVAMD, the diagnosis must have been made within 21 days prior to the Day 1 study treatment Key Incomplete Responder (IR) NVAMD-specific Inclusion Criteria * Be ≥ 50 years of age * Have subfoveal CNV secondary to AMD or juxtafoveal/extrafoveal CNV with foveal involvement at initial screening * For participants who are treatment experienced for NVAMD, the diagnosis must have been made within 90 days prior to the Screening Visit 2 Key Branch Retinal Vein Occlusion (BRVO)-specific Inclusion Criteria * Be diagnosed with BRVO in the study eye * Have a decrease in vision in the study eye determined by the Investigator to be primarily the result of BRVO * Be treatment naïve with vision loss in the study eye and have center-involving macular edema diagnosed within 9 months of Screening Exclusion Criteria: Key General Exclusion Criteria * Pregnant or breastfeeding * History of cataract surgery and/or minimally invasive glaucoma surgery in the study eye within 90 days of Screening * Have had Yttrium-Aluminum Garnet (YAG) laser capsulotomy in the study eye within 90 days of Screening * Currently using drugs with known retinal toxicity (e.g., Hydroxychloroquine, pentosan polysulfate sodium, and amiodarone) Key NVAMD-specific Exclusion Criteria * Have had previous thermal subfoveal laser therapy in the study eye * Have had previous photodynamic therapy with Visudyne in the study eye Key BRVO-specific Exclusion Criteria * Have macular edema in the study eye considered to be secondary to a cause other than BRVO (eg, diabetic macular edema, NVAMD, Irvine-Gass syndrome) * Have active iris or angle neovascularization or neovascular glaucoma in the study eye

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Branch retinal vein occlusion (BRVO) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

occlusion of tributary of retinal vein retinal vein occlusion wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Branch retinal vein occlusion (BRVO) Neovascular age-related macular degeneration (nvamd)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    55 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Abilene, Texas

    RECRUITING

    Abilene, Texas, 79606, United States

    Contact Email: •••••@•••••

  • Amarillo, Texas

    RECRUITING

    Amarillo, Texas, 79106, United States

    Contact Email: •••••@•••••

  • Asheville, North Carolina

    RECRUITING

    Asheville, North Carolina, 28803, United States

    Contact Email: •••••@•••••

  • Austin, TX

    RECRUITING

    Austin, Texas, 78705, United States

    Contact Email: •••••@•••••

  • Austin, Texas

    RECRUITING

    Austin, Texas, 78705, United States

    Contact Email: •••••@•••••

  • Bellaire, TX

    RECRUITING

    Bellaire, Texas, 77401, United States

    Contact Email: •••••@•••••

  • Bellaire, Texas

    RECRUITING

    Bellaire, Texas, 77401, United States

    Contact Email: •••••@•••••

  • Bloomfield, NJ

    RECRUITING

    Bloomfield, New Jersey, 07003, United States

    Contact Email: •••••@•••••

  • Bloomfield, New Jersey

    RECRUITING

    Bloomfield, New Jersey, 07003, United States

    Contact Email: •••••@•••••

  • Burleson, Texas

    RECRUITING

    Burleson, Texas, 76028, United States

    Contact Email: •••••@•••••

  • Cary, North Carolina

    RECRUITING

    Cary, North Carolina, 27511, United States

    Contact Email: •••••@•••••

  • Dallas, TX

    RECRUITING

    Dallas, Texas, 75231, United States

    Contact Email: •••••@•••••

  • Dallas, Texas

    RECRUITING

    Dallas, Texas, 75231, United States

    Contact Email: •••••@•••••

  • Florida Retina Institute

    RECRUITING

    Jacksonville, Florida, 32216, United States

  • Florida Retina Institute

    RECRUITING

    Orlando, Florida, 32806, United States

  • Fort Lauderdale, FL

    RECRUITING

    Fort Lauderdale, Florida, 33308, United States

    Contact Email: •••••@•••••

  • Fort Lauderdale, Florida

    RECRUITING

    Fort Lauderdale, Florida, 33308, United States

    Contact Email: •••••@•••••

  • Germantown, Tennessee

    RECRUITING

    Germantown, Tennessee, 38138, United States

    Contact Email: •••••@•••••

  • Glendale, CA

    RECRUITING

    Glendale, California, 91204, United States

    Contact Email: •••••@•••••

  • Glendale, California

    RECRUITING

    Glendale, California, 91204, United States

    Contact Email: •••••@•••••

  • Hagerstown, MD

    RECRUITING

    Hagerstown, Maryland, 21740, United States

    Contact Email: •••••@•••••

  • Hagerstown, Maryland

    RECRUITING

    Hagerstown, Maryland, 21740, United States

    Contact Email: •••••@•••••

  • Knoxville, Tennessee

    RECRUITING

    Knoxville, Tennessee, 37922, United States

    Contact Email: •••••@•••••

  • Lemont, IL

    RECRUITING

    Lemont, Illinois, 60439, United States

    Contact Email: •••••@•••••

  • Lemont, Illinois

    RECRUITING

    Lemont, Illinois, 60439, United States

    Contact Email: •••••@•••••

  • Long Island Vitreoretinal Consultants of NY

    RECRUITING

    Great Neck, New York, 11021, United States

  • Madison, MS

    RECRUITING

    Madison, Mississippi, 39110, United States

    Contact Email: •••••@•••••

  • Madison, Mississippi

    RECRUITING

    Madison, Mississippi, 39110, United States

    Contact Email: •••••@•••••

  • Modesto, California

    RECRUITING

    Modesto, California, 95356, United States

    Contact Email: •••••@•••••

  • Mountain View, California

    RECRUITING

    Mountain View, California, 94040, United States

    Contact Email: •••••@•••••

  • Nashville, TN

    RECRUITING

    Nashville, Tennessee, 37203, United States

    Contact Email: •••••@•••••

  • Nashville, Tennessee

    RECRUITING

    Nashville, Tennessee, 37203, United States

    Contact Email: •••••@•••••

  • North Carolina Retina Associates

    RECRUITING

    Greenville, North Carolina, 27834, United States

  • Plano, Texas

    RECRUITING

    Plano, Texas, 75075, United States

    Contact Email: •••••@•••••

  • RSC Research LLC

    RECRUITING

    Denver, Colorado, 80222, United States

  • Retina Consultants, PLLC

    RECRUITING

    Charleston, West Virginia, 25301, United States

  • Round Rock, TX

    RECRUITING

    Round Rock, Texas, 78681, United States

    Contact Email: •••••@•••••

  • Round Rock, Texas

    RECRUITING

    Round Rock, Texas, 78781, United States

    Contact Email: •••••@•••••

  • Sacramento, CA

    RECRUITING

    Sacramento, California, 95825, United States

    Contact Email: •••••@•••••

  • Sacramento, California

    RECRUITING

    Sacramento, California, 95841, United States

    Contact Email: •••••@•••••

  • Sactamento, California

    RECRUITING

    Sacramento, California, 95825, United States

    Contact Email: •••••@•••••

  • San Antonio, TX

    RECRUITING

    San Antonio, Texas, 78240, United States

    Contact Email: •••••@•••••

  • San Antonio, Texas

    RECRUITING

    San Antonio, Texas, 78240, United States

    Contact Email: •••••@•••••

  • San Marcos, Texas

    RECRUITING

    San Marcos, Texas, 78666, United States

    Contact Email: •••••@•••••

  • Santa Ana, California

    RECRUITING

    Santa Ana, California, 92705, United States

    Contact Email: •••••@•••••

  • Scottsdale, AZ

    RECRUITING

    Scottsdale, Arizona, 85255, United States

    Contact Email: •••••@•••••

  • Scottsdale, Arizona

    RECRUITING

    Scottsdale, Arizona, 85255, United States

    Contact Email: •••••@•••••

  • The Woodlands, TX

    RECRUITING

    The Woodlands, Texas, 77384, United States

    Contact Email: •••••@•••••

  • The Woodlands, Texas

    RECRUITING

    The Woodlands, Texas, 77384, United States

    Contact Email: •••••@•••••

  • Wake Forest, NC

    RECRUITING

    Wake Forest, North Carolina, 27587, United States

    Contact Email: •••••@•••••

  • Wake Forest, North Carolina

    RECRUITING

    Wake Forest, North Carolina, 27587, United States

    Contact Email: •••••@•••••

  • West Columbia, SC

    RECRUITING

    West Columbia, South Carolina, 29169, United States

    Contact Email: •••••@•••••

  • West Columbia, South Carolina

    RECRUITING

    West Columbia, South Carolina, 29169, United States

    Contact Email: •••••@•••••

  • West Jordan, Utah

    RECRUITING

    West Jordan, Utah, 84088, United States

    Contact Email: •••••@•••••

  • Willow Park, Texas

    RECRUITING

    Willow Park, Texas, 76087, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.